Literature DB >> 19371855

Mannose-binding lectin in high-risk human papillomavirus infection.

Ching-Chou Tsai1, Tsun-Mei Lin, Huey-Ling You, Hock-Liew Eng.   

Abstract

OBJECTIVE: Mannose-binding lectin (MBL) is a serum lectin that mediates phagocytosis and activates complement. We investigated the association of mbl-2 functional polymorphisms with human papillomavirus (HPV) infection, which is a primary etiologic factor for cervical cancer. STUDY
DESIGN: The frequencies of haplotypes and genotypes of mbl-2 exon1 and promoter region variants were analyzed in 150 patients with HPV and 277 control subjects with no HPV. Unconditional logistic regression analysis was performed to evaluate an association between specific mbl-2 alleles and susceptibility to HPV infection.
RESULTS: The frequency of high-producer mbl-2 genotypes was higher in patients with HPV than in control subjects with no HPV (P = .001). The genotype of the mbl-2 gene polymorphisms represented the least significant risk for the group with HPV.
CONCLUSION: Certain polymorphisms in the MBL promoter region are increased among cervical samples that demonstrate HPV infection. This finding suggests a potential link between MBL and high-risk HPV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19371855     DOI: 10.1016/j.ajog.2009.02.016

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Mannose-Binding Lectin Does Not Act as a Biomarker for the Progression of Preinvasive Lesions of Invasive Cervical Cancer.

Authors:  Carlos Afonso Maestri; Renato Nisihara; Guilherme P Ramos; Hellen Weinschutz Mendes; Iara Messias-Reason; Newton Sérgio de Carvalho
Journal:  Med Princ Pract       Date:  2017-11-07       Impact factor: 1.927

2.  Hepatitis B virus X protein binding to hepsin promotes C3 production by inducing IL-6 secretion from hepatocytes.

Authors:  Mingming Zhang; Jianxin Gu; Chunyi Zhang
Journal:  Oncotarget       Date:  2016-02-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.